Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from was processed by Pulse News Wire on March 6, 2026. It represents a primary source document for Japanese Ticker:4564 sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: March 06, 2026, 17:00 JST Published by Pulse News Wire: March 06, 2026, 17:05 JST OncoTherapy Science,Inc. [4564.T] TOKYO, Mar 06 (Pulse News Wire) – Oncotherapy Science,inc. (4564.T) announced today that it had requested the suspension of exercise for all remaining warrants of issue number 38 (with adjustment clause) held by Long Corridor Alpha Opportunities Master Fund, MAP246 Segregated Portfolio, and BEMAP Master Fund Ltd. The request was made based on the w